Is Innova Captab overvalued or undervalued?

As of 17 October 2025, the valuation grade for Innova Captab has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 35.46, an EV to EBITDA of 24.85, and a PEG ratio of 0.99, which suggests that the stock is priced favorably relative to its growth potential.
Innova Captab's valuation stands in contrast to its peers, such as Sun Pharma with a PE of 35.16 and an EV to EBITDA of 23.85, and Cipla, which is also rated attractive with a PE of 23.63. This comparison highlights that while Innova Captab's PE ratio is slightly higher, its PEG ratio indicates a more favorable growth outlook. Notably, the stock has underperformed against the Sensex in the year-to-date period, with a return of -27.15% compared to the Sensex's 7.44%, reinforcing the notion that it may be undervalued in the current market environment.